JDRF T1D Fund
JDRF T1D Fund is a venture philanthropy organization dedicated to identifying and supporting early-stage commercial opportunities in Type 1 Diabetes research. By partnering with private capital, including venture capital, pharmaceutical companies, and other foundations, the fund aims to accelerate the development of treatments, preventions, and cures for T1D patients. With a focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, the fund prioritizes the most promising commercial opportunities in the field. Any profits generated are reinvested into new investments to advance the mission of finding a cure for Type 1 Diabetes.
Top Stages
Past deals in South Dakota
SAb Biotherapeutics
Post in 2023
SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.